Tesevatinib
Tesevatinib (XL-647) is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR) . Tesevatinib significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM) . Tesevatinib can inhibit tumor proliferation and exhibits antitumor activity[1][2].
Product Specifications
CAS Number
781613-23-8
Product Name Alternative
XL-647; EXEL-7647; KD-019
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR; Src; VEGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/XL-647.html
Purity
99.41
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
[H][C@@]12[C@@](C[C@@H](COC3=CC4=C(C(NC5=C(F)C(Cl)=C(Cl)C=C5)=NC=N4)C=C3OC)C2)([H])CN(C)C1
Molecular Formula
C24H25Cl2FN4O2
Molecular Weight
491.39
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant SARS-CoV-2 Spike RBD (A520V) (His Tag)
NKX2.2 (Neuroendocrine & Ewing s Sarcoma Marker) (NX2/1422R), CF488A conjugate, 0.1mg/mL
